Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC.19 ▼AHA 2019 ▼Diabetes & CVD ▼EAS 2019 ▼ESC 2019 ▼ESC Diabetes guidelines 2019 ▼ESC/EAS Guidelines dyslipidaemias 2019 ▼HFpEF: The essentials to know ▼LDL-c Expert Meeting ▼LDL-c Key Lessons ▼PCSK9 ▼

CVMC

Slides (curriculum) - May 9, 2013

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Oral load of colchicine prior to PCI prevents a rise of inflammatory biomarkers in acute injury

News - Nov. 18, 2019

Identification of parameters associated with plaque erosion in STEMI and NSTE-ACS

Literature - Oct. 30, 2019 - Yamamoto E et al., - J Am Heart Assoc. 2019

P2Y12i monotherapy reduces ischemic outcomes in patients undergoing multivessel PCI

Literature - Oct. 28, 2019 - Takahashi K, et al. - J Am Coll Cardiol 2019

Atherosclerosis

Interim data study into effects of fish oil on plaque progression shows promising findings

News - Nov. 18, 2019

Identification of parameters associated with plaque erosion in STEMI and NSTE-ACS

Literature - Oct. 30, 2019 - Yamamoto E et al., - J Am Heart Assoc. 2019

Long-term safety and LDL lowering with PCSK9 inhibition in hypercholesterolemic patients

Literature - Oct. 29, 2019 - Koren MJ et al. - J Am Coll Cardiol 2019

Atrial fibrillation

Rate, trends and predictors of early mortality after AF ablation

Literature - Nov. 7, 2019 - Cheng EP, et al. - J Am Coll Cardiol 2019

Lower risk of osteoporotic fractures in AF patients with DOAC vs. VKA treatment

Literature - Oct. 29, 2019 - Binding C, et al. - J Am Coll Cardiol 2019

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

CV Inflammation

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

Generic anti-inflammatory drug lowers ischemic events in patients with recent MI

News - Nov. 16, 2019

CVRM

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

Not only weight loss, but also maintaining a lower weight is important for a good CV risk profile

Literature - Oct. 14, 2019 - Berger SE et al., - J Am Heart Assoc. 2019

Parental smoking increases AF risk in offspring

Literature - Oct. 10, 2019 - Groh CA et al., - J Am Coll Cardiol 2019

Diabetes

BET inhibitor therapy did not reduce MACE in high risk, well-treated patients with T2DM

News - Nov. 17, 2019

SGLT2i gives consistent CV benefit in HFrEF patients with or without T2DM

News - Nov. 16, 2019

Decrease in eGFR associated with future risk of renal and CV events in patients with T2DM

Literature - Nov. 4, 2019 - Oshima M et al., - Diabetologia 2019

Epigenetics in CVD

BET inhibitor therapy did not reduce MACE in high risk, well-treated patients with T2DM

News - Nov. 17, 2019

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Long-term safety and LDL lowering with PCSK9 inhibition in hypercholesterolemic patients

Literature - Oct. 29, 2019 - Koren MJ et al. - J Am Coll Cardiol 2019

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Initiating statin therapy in children with FH reduces subclinical and clinical atherosclerotic disease

Literature - Oct. 22, 2019 - Luirink IK et al., - N Engl J Med 2019

GLP-1 RA & CVD

Subgroup analyses in GLP1-RA trial meta-analysis to understand the varying outcomes seen with different GLP-1RAs

Literature - Oct. 22, 2019 - Kristensen SL et al., - Lancet Diabetes Endocrinol. 2019

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart Failure

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

ARNI treatment effect across EF spectrum: benefit up to mildly reduced EF

News - Nov. 17, 2019

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Thiazide or thiazide-like diuretics superior to ACEi as initial monotherapy in hypertension

Literature - Nov. 12, 2019 - Suchard MA, et al. - The Lancet 2019

Hypertension medication ingestion at bedtime improves asleep ABP and reduces CVD risk

Literature - Oct. 31, 2019 - Hermida RC et al., - Eur Heart J 2019

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

BET inhibitor therapy did not reduce MACE in high risk, well-treated patients with T2DM

News - Nov. 17, 2019

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Potent and durable LDL-c lowering up to 18 months with siRNA against PCSK9

News - Nov. 16, 2019

Lp(a)

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD

High Lp(a) levels associate with mortality, through low number of Kringle-IV type 2 repeats

Literature - Sep. 16, 2019 - Langsted A, et al. - Eur Heart J 2019

New ESC/EAS dyslipidemia guidelines advocate “lower is better” for LDL-c

News - Sep. 1, 2019

PCSK9

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Potent and durable LDL-c lowering up to 18 months with siRNA against PCSK9

News - Nov. 16, 2019

Long-term safety and LDL lowering with PCSK9 inhibition in hypercholesterolemic patients

Literature - Oct. 29, 2019 - Koren MJ et al. - J Am Coll Cardiol 2019

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key questions addressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Optimism associated with reduced risk of CV events and all-cause mortality

Literature - Oct. 10, 2019 - Rozanski A, et al. - JAMA Network Open

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Systolic and diastolic hypertension independently associated with CV outcomes

Literature - July 22, 2019 - Flint AC et al. - N Engl J Med 2019

© 2006 - 2019 pace-cme.org - About